Stocks and Investing Stocks and Investing
Wed, December 22, 2021
Tue, December 21, 2021

Steve Valiquette Maintained (AMED) at Buy with Decreased Target to $213 on, Dec 21st, 2021


Published on 2024-10-27 19:04:36 - WOPRAI, Steve Valiquette
  Print publication without navigation


Steve Valiquette of Barclays, Maintained "Amedisys, Inc." (AMED) at Buy with Decreased Target from $236 to $213 on, Dec 21st, 2021.

Steve has made no other calls on AMED in the last 4 months.



There are 9 other peers that have a rating on AMED. Out of the 9 peers that are also analyzing AMED, 3 agree with Steve's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Scott Fidel of "Stephens & Co." Maintained at Hold with Increased Target to $185 on, Thursday, November 4th, 2021
  • Whit Mayo of "SVB Leerink" Maintained at Hold with Increased Target to $181 on, Thursday, November 4th, 2021
  • Gary Taylor of "Cowen & Co." Initiated at Hold and Held Target at $195 on, Friday, September 10th, 2021


These are the ratings of the 6 analyists that currently disagree with Steve


  • John Ransom of "Raymond James" Maintained at Buy with Decreased Target to $225 on, Monday, November 8th, 2021
  • Jonathan Yong of "Credit Suisse" Maintained at Buy with Increased Target to $205 on, Thursday, November 4th, 2021
  • Frank Morgan of "RBC Capital" Maintained at Buy with Decreased Target to $221 on, Thursday, November 4th, 2021
  • Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $225 on, Wednesday, November 3rd, 2021
  • David Macdonald of "Truist Securities" Maintained at Strong Buy with Decreased Target to $190 on, Wednesday, October 13th, 2021
  • Andrew Mok of "UBS" Initiated at Strong Sell and Held Target at $150 on, Friday, September 24th, 2021
Contributing Sources